MISTIE III Trial

Last edited and medically reviewed by on

The results of the MISTIE III study were published in 2019[^1]. This study investigated whether patients with a supratentorial intracerebral hemorrhage benefit from minimally invasive catheter-based hematoma evacuation followed by thrombolysis.

Study Results

The study found no better functional outcome at one year among patients in the MISTIE group[^1].

MISTIE III Trial
Figure adapted from the original MISTIE III publication on functional outcome after one year.
MISTIE III Trial
Figure adapted from the original MISTIE III publication on overall survival over the course of one year.

Authors’ Interpretation

For moderate to large intracerebral hemorrhage, MISTIE did not improve the proportion of patients who achieved a good response 365 days after intracerebral hemorrhage. The procedure was safely adopted by our sample of surgeons.[^1]

Editorial transparency

Authorship & revisions

Who created and updated this article, and which changes are documented.

Article created by
Last edited:
on
Revision history
3 edits · 1 contributor
Author list:
Show revision history 3 entries

3 edits by 1 author

Edit · Alaric Steinmetz ·

No content change recorded

Edit · Alaric Steinmetz · (+13 −11)
  • Text added: “Authors’ Interpretation”
  • Text changed: “The results of the MISTIE III trial were published in 2019[^1]. This study investigated whether patients with a supratentorial intracerebral hemorrhage benefit from minimally invasive hematoma evacuation via a catheter followed by thrombolysis.”“The results of the MISTIE III study were published in 2019[^1]. This study investigated whether patients with a supratentorial intracerebral hemorrhage benefit from minimally invasive catheter-based hematoma evacuation followed by thrombolysis.”
  • Text changed: “Study results”“Study Results”
  • Text changed: “The study did not demonstrate better functional outcomes after one year in patients in the MISTIE group[^1].”“The study found no better functional outcome at one year among patients in the MISTIE group[^1].”
  • Citation added: “Hanley, Daniel F., et al. "Efficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation (MISTIE III): a randomised, controlled, open-label, blinded endpoint phase 3 trial." The Lancet 393.10175 (2019): 1021-1032.”

Article created on · Alaric Steinmetz

Image viewer

Image

Open original